102 related articles for article (PubMed ID: 19227559)
41. Using registries to monitor HIV pre-exposure prophylaxis safety in clinical settings.
Tilson HH
Am J Prev Med; 2013 Jan; 44(1 Suppl 2):S151-5. PubMed ID: 23253758
[No Abstract] [Full Text] [Related]
42. Miriam Hospital launches new HIV prevention program: PrEP program offers daily pill that can help prevent HIV infection.
R I Med J (2013); 2014 Jan; 97(1):57. PubMed ID: 24960871
[No Abstract] [Full Text] [Related]
43. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
[TBL] [Abstract][Full Text] [Related]
44. FTC superiority over d4T in phase III trial.
Berger DS
Posit Aware; 2002; 13(5):48, 53. PubMed ID: 12400496
[No Abstract] [Full Text] [Related]
45. Apricitabine continues to show good results.
Dalton P
Proj Inf Perspect; 2008 Sep; (46):12. PubMed ID: 19043879
[No Abstract] [Full Text] [Related]
46. Response to the comparison of generic zidovudine plus lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets.
Narang VS; Desai A; Purandare S
J Acquir Immune Defic Syndr; 2004 Dec; 37(4):1540-1. PubMed ID: 15602135
[No Abstract] [Full Text] [Related]
47. Apricitabine: a nucleoside reverse transcriptase inhibitor for HIV infection.
Gaffney MM; Belliveau PP; Spooner LM
Ann Pharmacother; 2009 Oct; 43(10):1676-83. PubMed ID: 19737995
[TBL] [Abstract][Full Text] [Related]
48. Comparison of generic zidovudine + lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets.
Henry K; Brundage R; Weller D; Akinsete O; Shet A
J Acquir Immune Defic Syndr; 2004 Apr; 35(5):537. PubMed ID: 15021319
[No Abstract] [Full Text] [Related]
49. Breaking down lipodystrophy.
Nutr Healthy Living; 2000; 5(1):4. PubMed ID: 11682763
[No Abstract] [Full Text] [Related]
50. Proof of principal studies to assess the role of the human betaretrovirus in patients with primary biliary cirrhosis.
Mason A; Xu L; Neuberger J
Am J Gastroenterol; 2004 Dec; 99(12):2499-500. PubMed ID: 15571601
[No Abstract] [Full Text] [Related]
51. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
Tsuchiya N; Pathipvanich P; Yasuda T; Mukoyama Y; Rojanawiwat A; Matsubayashi T; Saeng-aroon S; Auwanit W; Matsuyama A; Sawanpanyalert P; Ariyoshi K
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):71-82. PubMed ID: 19323037
[TBL] [Abstract][Full Text] [Related]
52. Zidovudine and the quality of life.
Berman DS; Wenglin BD
N Engl J Med; 1994 Aug; 331(5):332-3. PubMed ID: 8022458
[No Abstract] [Full Text] [Related]
53. FDA notifications. Generic lamivudine/zidovudine approved.
AIDS Alert; 2009 Jul; 24(7):82. PubMed ID: 19705578
[No Abstract] [Full Text] [Related]
54. Interim guidance for PrEP in MSM. CDC: Do not expand to other risk groups yet.
AIDS Alert; 2011 Apr; 26(4):44-5. PubMed ID: 21623623
[No Abstract] [Full Text] [Related]
55. Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities.
Guaraldi G; Baraboutis IG
J Antimicrob Chemother; 2009 Sep; 64(3):437-40. PubMed ID: 19578082
[TBL] [Abstract][Full Text] [Related]
56. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
[TBL] [Abstract][Full Text] [Related]
57. Reflections: neurology and the humanities: reflections for October.
Birbeck GL
Neurology; 2009 Oct; 73(15):1245-6. PubMed ID: 19822877
[No Abstract] [Full Text] [Related]
58. Counterfit drugs: check Combivir, Serostim, Epogen.
James JS
AIDS Treat News; 2002 May; (380):3-4. PubMed ID: 12085844
[No Abstract] [Full Text] [Related]
59. [Adipose tissue hypertrophy after Lipostructure in HIV patient with antiretroviral treatment. Case report and literature review].
Rousvoal A; Délia G; Casoli V; Martin D
Ann Chir Plast Esthet; 2009 Aug; 54(4):384-7. PubMed ID: 19223106
[TBL] [Abstract][Full Text] [Related]
60. Gay community to test HIV prevention pill.
Bateman C
S Afr Med J; 2008 Sep; 98(9):660-1. PubMed ID: 19113040
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
